(以下内容从西南证券《医药行业周报:二十届四中全会明确推进健康中国,十五五规划建议明确支持创新药械发展》研报附件原文摘录)投资要点行情回顾:本周医药生物指数上涨0.58%,跑输沪深300指数2.67个百分点,行业涨跌幅排名第26。2025年初以来至今,医药行业上涨19.54%,跑赢沪深300指数1.09个百分点,行业涨跌幅排名第12。本周医药行业估值水平(PE-TTM)为30.36倍,相对全部A股...
Source Link(以下内容从西南证券《医药行业周报:二十届四中全会明确推进健康中国,十五五规划建议明确支持创新药械发展》研报附件原文摘录)投资要点行情回顾:本周医药生物指数上涨0.58%,跑输沪深300指数2.67个百分点,行业涨跌幅排名第26。2025年初以来至今,医药行业上涨19.54%,跑赢沪深300指数1.09个百分点,行业涨跌幅排名第12。本周医药行业估值水平(PE-TTM)为30.36倍,相对全部A股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.